Cardiovascular Risk Assessment for Persons Living With HIV

Journal of the Association of Nurses in AIDS Care

Volumn 23, Issue 2, 2012, Pages 134-145

  Burke, Emily G ^a   Nelson, Joan ^b   Kwong, Jeffrey ^c   Cook, Paul F ^b  

^a Sheridan Health Services   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c New Jersey   (United States)

Author keywords

Cardiovascular disease; Framingham risk; HIV; Lipid management; Patient education and counseling; Quality improvement; Therapeutic lifestyle change

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; LIFESTYLE; MALE; MASS SCREENING; MIDDLE AGED; NEEDS ASSESSMENT; PATIENT EDUCATION; RISK ASSESSMENT; SMOKING; TOTAL QUALITY MANAGEMENT; UNITED STATES;

ADULT; CARDIOVASCULAR DISEASES; COLORADO; COMORBIDITY; FEMALE; HIV INFECTIONS; HUMANS; HYPERCHOLESTEROLEMIA; LIFE STYLE; MALE; MASS SCREENING; MIDDLE AGED; NEEDS ASSESSMENT; PATIENT EDUCATION AS TOPIC; QUALITY IMPROVEMENT; RISK ASSESSMENT; SMOKING; YOUNG ADULT;

EID: 84856969161     PISSN: 10553290     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jana.2011.05.007     Document Type: Article

References (24)

1. Aberg J. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinology Metabolism Clinics of North America 2009, 38:207-222. 10.1016/j.ecl.2008.11.009.
2. Calza L., Verucchi G., Pocaterra D., Pavoni M., Alfieri A., Cicognani A., Chiodo F., et al. Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection. International Journal of STDs and AIDS 2009, 10:389-683. 10.1258/ijsa.2009.008504.
3. Das S. Evaluation of cardiovascular risk in HIV patients: Clinical implication. The International Journal of Clinical Practice 2010, 64(9):1169-1175. 10.1111/j.1742-1241.2010.02457.x.
4. Dube M., Stein J., Aberg J., Fichtenbaum C., Gerber J., Tashima K., Glesby M.J., et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clinical Infectious Disease 2003, 37:613-627. 10.1086/378131.
5. Friis-Moller N., Thiébaut R., Reiss P., Weber R., D'Arminio A., De Wit S., Law M.G., et al. Predicting the risk of cardiovascular disease in HIV-infected patients: The Data Collection on Adverse Events of Anti-HIV Drugs Study. European Journal of Cardiovascular Prevention and Rehabilitation 2010, 17:491-501. 10.1097/HJR.0b013e328336a150.
6. George E., Lucas G., Nadkarni G., Fine D., Moore R., Atta M.G. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS 2010, 24:387-394. 10.1097/QAD.0b013e3283359253.
7. Grover S., Coupal L., Gilmore N., Mukherjee J. Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy. American Journal of Cardiology 2005, 95:586-591. 10.1016/j.amjcard.2004.11.004.
8. Hardwicke R., Lewis S., Grimes R. Evaluation and pharmacologic management of the HIV-infected patient with dyslipidemia. Journal of the Association of Nurses in AIDS Care 2010, 21(5):429-438. 10.1016/j.jana.2009.12.006.
9. Kannel W., Giordano M. Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia. American Journal of Cardiology 2004, 94:901-906. 10.1016/j.amjcard.2004.06.025.
10. Knobel H., Jerico C., Montero M., Sorli M., Velat M., Guelar A., Pedro-Botet J., et al. Global cardiovascular risk in patients with HIV infection: Concordance and differences in estimates according to three risk equations (Framingham, SCORE, PROCAM). AIDS Patient Care and STDs 2007, 21(7):452-457. 10.1089/apc.2006.0165.
11. Kwong J., Bouchard-Miller K. Smoking cessation for persons living with HIV: A review of currently available interventions. Journal of the Association of Nurses in AIDS Care 2010, 21:3-10. 10.1016/j.jana.2009.03.007.
12. Lenth, R. V. (2006-9). Java Applets for Power and Sample Size [Computer software]. Retrieved from http://www.stat.uiowa.edu/~rlenth/Power/index.html.
13. Law M., Friis-Moller N., El-Sadr W., Weber R., Reiss P., Monforte A., Lundgran J.D., et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: Comparison with observed events in the D: A:D study. HIV Medicine 2006, 7:218-230. 10.1111/j.1468-1293.2006.00362.x.
14. Lima E., Gualandro D., Yu P., Giuliano I., Marques A., Calderaro D., Caramelli D. Cardiovascular prevention in HIV patients: Results from a successful intervention program. Artherosclerosis 2009, 204:229-232. 10.1016/j.atherosclerosis.2008.08.017.
15. Lo J., Abbara S., Shturman L., Soni A., Wei J., Rocha-Filho J., Grinspoon S.K., et al. Increased prevalence of subclinical coronary arthrosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010, 24:243-253. 10.1097/QAD.0b013e328333ea9e.
16. Lundgren J., Mattegay M., Behrens G., De Wit S., Guaraldi G., Katlama C., Sutinen J., et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic disease in HIV. HIV Medicine 2008, 9:72-81. 10.1111/j.1468-1293.2007.00534.x.
17. National Institutes of Health. (2002). Third report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Retrieved from http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf.
18. McGoldrick C., Leen C.L.S. The management of dyslipidemia in antiretroviral-treated HIV infection: A systematic review. HIV Medicine 2007, 8:325-334. 10.1111/j.1468-1293.2007.00480.x.
19. Modrich, L., Scherzer, R., Zolopa, A., Rimland, D., Lewis, C., Bacchetti, P.,.... Tien, P., (2009). Factors associated with mortality in the study of fat redistribution and metabolic change in HIV infection. Paper presented at 16th Conference on Retroviruses and Opportunistic Infections, Abstract #706. Montreal, Canada.
20. Parra S., Coll B., Aragones G., Marsillach J., Beltran R., Rull A., Camps J., et al. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: Relationships with serum markers of oxidation and inflammation. HIV Medicine 2010, 11:225-231. 10.1111/j.1468-1293.2009.00766.x.
21. Randell P., Moyle G. Antiretroviral therapy with heart. American Journal of Therapeutics 2009, 16:579-584. 10.1097/MJT.0b013e318192116f.
22. Schambelan M., Wilson P., Yarasheski K., Cade T., Davila-Roman V., Agostino R., Worm S.W., et al. Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. Circulation 2008, 118:e48-e53. 10.1161/CIRCULATIONAHA.107.189627.
23. Sheridan S., Viera A., Krantz M., Ice C., Steinman L., Peters K., Lungelow D., et al. The effect of giving global coronary risk information to adults. Archives of Internal Medicine 2010, 170(3):230-239.
24. Smith, C. (2009). Association between modifiable and non-modifiable risk factors and specific causes of death in the HAART era: The Data Collection of Adverse Events of Anti-HIV Drugs study (D:A:D). Abstract #145. Paper presented at 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada.